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ABSTRACT
Objective A hallmark of chronic HBV (cHBV) infection 
is the presence of impaired HBV-specific CD8+ T cell 
responses. Functional T cell exhaustion induced by 
persistent antigen stimulation is considered a major 
mechanism underlying this impairment. However, due to 
their low frequencies in chronic infection, it is currently 
unknown whether HBV-specific CD8+ T cells targeting 
different epitopes are similarly impaired and share 
molecular profiles indicative of T cell exhaustion.
Design By applying peptide-loaded MHC I tetramer-based 
enrichment, we could detect HBV-specific CD8+ T cells 
targeting epitopes in the HBV core and the polymerase 
proteins in the majority of 85 tested cHBV patients with 
low viral loads. Lower detection rates were obtained 
for envelope-specific CD8+ T cells. Subsequently, we 
performed phenotypic and functional in-depth analyses.
Results HBV-specific CD8+ T cells are not terminally 
exhausted but rather exhibit a memory-like phenotype 
in patients with low viral load possibly reflecting weak 
ongoing cognate antigen recognition. Moreover, HBV-
specific CD8+ T cells targeting core versus polymerase 
epitopes significantly differed in frequency, phenotype 
and function. In particular, in comparison with core-
specific CD8+ T cells, a higher frequency of polymerase-
specific CD8+ T cells expressed CD38, KLRG1 and Eomes 
accompanied by low T-bet expression and downregulated 
CD127 indicative of a more severe T cell exhaustion. 
In addition, polymerase-specific CD8+ T cells exhibited 
a reduced expansion capacity that was linked to a 
dysbalanced TCF1/BCL2 expression.
Conclusions Overall, the molecular mechanisms 
underlying impaired T cell responses differ with respect to 
the targeted HBV antigens. These results have potential 
implications for immunotherapeutic approaches in HBV 
cure.
INTRODUCTION
Virus-specific CD8+ T cells play a central 
role in the elimination of HBV infection and 
are thus considered promising targets for 
Significance of this study
What is already known on this subject?
 ► HBV-specific CD8+ T cells play a central role in 
the elimination of HBV infection.
 ► Frequencies of HBV-specific CD8+ T cells in 
chronic HBV infection are very low reflected 
by low detection rates applying ex vivo 
peptide-loaded MHC I (pMHC I) tetramer 
staining.
 ► Detectable HBV-specific CD8+ T cells are 
functionally impaired, exhibit mitochondrial 
alterations, express inhibitory receptors and 
display dysregulation of T-bet.
What are the new findings?
 ► By applying a pMHC I tetramer-based enrichment 
strategy, we could detect HBV-specific CD8+ T 
cells in the majority of chronically HBV-infected 
patients.
 ► Env183-specific CD8+ T cells are hardly detectable 
by pMHC I tetramer-based enrichment in 
chronically HBV-infected patients.
 ► HBV-specific CD8+ T cells targeting core18/141 
and pol455/173 epitopes are not terminally 
exhausted but predominantly exhibit  
a memory-like phenotype in chronic  
infection.
 ► Core18/141 and pol455/173-specific CD8+ T cells 
differ in frequency, phenotype and function in 
chronic HBV infection but not in resolved HBV 
infection.
 ► Dysregulated TCF1/BCL2 expression limits the 
expansion capacity of pol455/173-specific CD8+ T 
cells in chronic HBV infection.
How might it impact on clinical practice in the 
foreseeable future?
 ► These findings have potential implications for the 
design of T cell-targeted therapeutic approaches 
in HBV cure.
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immunotherapeutic approaches to cure chronic HBV (cHBV) 
infection. However, for the design of efficient immunother-
apies, a better understanding of HBV-specific CD8+ T cell 
biology, especially of the dominant antigen targets and their 
distinct functional characteristics coupled to the respective 
underlying molecular mechanisms and the corresponding 
phenotypic profile, is required.
Insights into HBV-specific CD8+ T cell responses were mostly 
gained by conventional ex vivo peptide-loaded MHC I (pMHC 
I) tetramer staining and after in vitro expansion. These analyses 
revealed that the frequencies of HBV-specific CD8+ T cells in 
cHBV infection are overall very low and associated with the 
stage of disease.1 Indeed, ex vivo detectability of HBV-specific 
CD8+ T cells in patients with cHBV is mainly limited to indi-
viduals with low viral loads1–7 with detection rates of only 20% 
of patients even in non-replicative inactive HBsAg carriers.8 The 
reason for the low detection rate of HBV-specific CD8+ T cells is 
largely unknown. One possibility might be deletion of HBV-spe-
cific CD8+ T cells in patients with cHBV as supported by the 
finding of elevated expression of the proapoptotic molecule 
Bim.9 Nevertheless, it has been shown that the few detectable 
HBV-specific CD8+ T cells are functionally impaired, express 
several inhibitory receptors5 8 10–14 and display a dysregulation 
of the transcription factor T-bet.7 These findings are indicative 
of T cell exhaustion in cHBV infection. Recently, ex vivo tran-
scriptome analyses of HBV-specific CD8+ T cells revealed that 
mitochondrial alterations contribute to this functional exhaus-
tion.15 However, due to the aforementioned low frequency of 
HBV-specific CD8+ T cells present in patients with cHBV and 
the technical limitations of classical immune assays, a compar-
ative knowledge about ex vivo frequencies, molecular profiles 
and functional characteristics of HBV-specific CD8+ T cells 
targeting different epitopes is still lacking.
Newly established, highly sensitive technologies have intro-
duced the possibility of comprehensive in-depth analyses of 
such rare cell populations. Indeed, by applying a pMHC I 
tetramer-based enrichment strategy, we have recently been 
able to identify heterogeneous memory-like and terminally 
exhausted subsets of low frequency HCV-specific CD8+ T cell 
populations targeting the same epitope.16 Importantly, 
CD127+PD1+ memory-like HCV-specific CD8+ T cells are 
maintained after cessation of persistent antigen recognition 
and harbour the proliferative potential that is determined by 
the transcription factor TCF1. Here, by adapting the pMHC 
I tetramer-based enrichment strategy, we were able to detect 
HBV-specific CD8+ T cells targeting HLA-A*02-restricted 
polymerase455-463 (pol455) and core18-27 (core18) epitopes in the 
majority of cHBV patients with low viral load. However, the 
detection rate of envelope183-191 (env183)-specific CD8+ T cells 
was low. Subsequent in-depth analyses revealed that HBV-spe-
cific CD8+ T cells are not terminally exhausted but rather 
exhibit a less differentiated, TCF1+ memory-like phenotype 
in these patients possibly reflecting very weak ongoing cognate 
antigen recognition. Furthermore, we demonstrate that 
pol455-specific compared with core18-specific CD8+ T cells 
are present in different frequencies and exhibit phenotypically 
and functionally different characteristics that were reproduc-
ible also for non-HLA-A*02-restricted core141-160 (core141) and 
pol173-181 (pol173) epitopes. Specifically, limited expansion of 
pol455/173-specific but not core18/141-specific CD8+ T cells was 
linked to dysregulated TCF1/BCL2 expression demonstrating 
different molecular mechanisms underlying core-specific and 
pol-specific CD8+ T cell impairment.
EXPERIMENTAL PROCEDURES
Study cohort
Eighty-eight patients with cHBV, 10 patients with resolved 
HBV infection (rHBV) and 6 chronically HCV-infected (cHCV) 
patients were recruited at the Department of Medicine II of the 
University Hospital Freiburg, Germany. Viral load and trans-
aminases were determined as part of the clinical diagnostics at 
the University Hospital Freiburg. Patients with liver cirrhosis 
were excluded from the study. Detailed patient characteristics 
are listed in table 1 and online supplementary SI tables 1–4. 
Twelve healthy donors (HD) served as controls. Human leuko-
cyte antigen (HLA)-typing was performed by next-generation 
sequencing. Written informed consent was obtained in all cases.
Peptides and tetramers
Peptides of HLA-A*02-restricted, HLA-A*11-restricted 
and HLA-B*35-restricted HBV-derived epitopes (core18: 
FLPSDFFPSV, pol455: GLSRYVARL, env183: FLLTRILTI, core141: 
STLPETVVRR, pol173: SPYSWEQEL), HLA-A*02-restricted 
HCV-derived epitopes (NS31073: CINGVCWTV, NS31406: KLVAL-
GINAV) and HLA-A*02-restricted cytomegalovirus-derived 
epitope pp65495 (NLVPMVATV) were obtained from Genaxxon, 
Germany, and dissolved in DMSO (Sigma, Germany). pMHC I 
tetramers were generated by conjugation of biotinylated pMHC 
I monomers with phycoerythrin (PE)-conjugated or allophyco-
cyanin (APC)-conjugated streptavidin.
pMHC I tetramer-based magnetic bead enrichment of virus-
specific CD8+ T cells
Enrichment of virus-specific CD8+ T cells was performed as 
previously described.17 Briefly, 2−3×107 peripheral blood 
mononuclear cells (PBMCs) were labelled for 30 min with 
PE-coupled or APC-coupled pMHC I tetramers. Subsequent 
enrichment was performed with anti-PE/APC beads applying 
MACS technology (Miltenyi Biotec, Germany) according to the 
manufacturer’s protocol. Frequencies of virus-specific CD8+ T 
cells were calculated as described previously.17
Expansion of virus-specific CD8+ T cells and assessment of 
effector function
PBMCs (1−2×106) were stimulated with epitope-specific 
peptides (10 µg/mL) and anti-CD28 mAb (0.5 µg/mL, BD) and 
expanded for 14 days in rIL2-containing (20 IU/mL, Miltenyi 
Biotec) complete RPMI culture medium. The expansion factor 
was calculated based on pMHC I tetramer staining as previ-
ously described.16 Cytokine production and degranulation 
were assessed after 6-hour restimulation with epitope-specific 
peptides as described before.16
Statistics
Statistical analysis was performed with GraphPad Prism 6 (USA) 
and is indicated in the figure legends. Levels of significance 
are indicated as follows: *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001.
RESULTS
pMHC I tetramer-based enrichment reveals presence of 
core18-specific and pol455-specific CD8+ T cells in the majority 
of cHBV patients with low viral load
HBV-specific CD8+ T cells targeting three well-described 
HLA-A*02-restricted epitopes, core18, pol455, and env183, were 
analysed in a large cohort of 49 patients with cHBV (HBsAg+, 
HBeAg−) with low viral load (table 1). Previously, we were 
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only able to detect HBV-specific CD8+ T cells in about 20% 
of these patients by ex vivo analysis.8 To increase the detection 
rate and to allow a subsequent comprehensive phenotypic and 
functional analysis of these rather very low frequency popu-
lations, we performed pMHC I tetramer-based enrichment 
(figure 1A). Indeed, by using this approach, we were able to 
detect HBV-specific CD8+ T cells in about 80% (39/49) of 
analysed patients (figure 1B). Specifically, core18-specific and 
pol455-specific CD8+ T cells were detectable in 87% (20/23) and 
66.7% (22/33) of analysed patients, respectively (figure 1C). 
Table 1 Study cohort of HLA-A*02-positive cHBV patients with low viral load 
Patient ID Age (years) Sex VL (IU/mL) HBsAg (IU/mL) ALT (U/L) Therapy WT viral sequences
Detectable 
CD8+ T cell response
cHBV1 31 M 1863 5920.66 36 Naive core18, env183 core18
cHBV2 45 F 1965 3.96 27 Naive core18, pol455 core18, pol455
cHBV3 42 F 889 925.22 15 Naive core18 core18
cHBV4 52 F 2425 786.77 36 Naive core18, env183 core18
cHBV5 38 M 2530 14.08 45 Naive pol455 –
cHBV6 40 F 672 888.65 20 Naive env183, pol455 pol455
cHBV7 58 F 136 10.87 14 Naive env183, pol455 env183, pol455
cHBV8 55 M 502 7751.10 33 Naive env183, pol455 env183, pol455
cHBV9 53 M 41 10.45 21 Naive core18 core18
cHBV10 29 F 306 652.63 14 Naive core18, env183 core18, env183
cHBV11 77 F 367 230.79 20 Naive core18, pol455 core18, pol455
cHBV12 25 F 34 67.48 20 Naive core18, env183 core18
cHBV13 51 M 157 90.81 20 Naive core18 core18
cHBV14 55 F 87 172.98 22 Naive core18 core18
cHBV15 61 M 1335 180.28 56 Naive core18 core18
cHBV16 54 M 301 28.83 24 Naive core18 core18
cHBV17 28 M 270 397.5 39 Naive core18 core18
cHBV18 63 F 922 21.96 28 Naive core18, env183, pol455 core18
cHBV19 34 M 345 215.07 83 Naive env183, pol455 pol455
cHBV20 33 F 1085 796.49 21 Naive core18, env183, pol455 core18, pol455
cHBV21 42 F 2662 233.66 16 Naive env183, pol455 – 
cHBV22 40 M 347 24.33 30 Naive env183, pol455 – 
cHBV23 49 F nd 605.37 8 Naive env183, pol455 – 
cHBV24 46 M 1375 31 501 56 Naive env183, pol455 – 
cHBV25 36 F 44 5998.51 38 Naive core18, env183 env183
cHBV26 40 F 153 6667.23 24 Naive pol455 – 
cHBV27 58 F 1842 52.80 19 Naive pol455 pol455
cHBV28 47 F 657 301.06 11 Naive env183 env183
cHBV29 40 F 189 nd 26 Naive env183 – 
cHBV30 66 M 293 2409.22 19 Adefovir core18, env183, pol455 core18, pol455
cHBV31 32 M 146 315.73 58 Entecavir pol455 pol455
cHBV32 53 F nd 963.42 18 Entecavir core18, env183, pol455 pol455
cHBV33 28 F 665 8287.79 44 Entecavir core18, env183, pol455 pol455
cHBV34 47 F 50 2899.17 22 Entecavir pol455 pol455
cHBV35 53 M <10 15 623.52 54 Entecavir core18, env183, pol455 core18, pol455
cHBV36 53 M <10 1394.3 31 Entecavir core18 core18
cHBV37 46 F 12 2190.76 33 Entecavir env183, pol455 pol455
cHBV38 37 M <10 3444.03 55 Entecavir env183, pol455 – 
cHBV39 27 F <10 1432.94 27 Lamivudine pol455 – 
cHBV40 51 M <10 215.9 42 Telbivudine env183, pol455 pol455
cHBV41 31 M 60 2338.44 31 Telbivudine env183, pol455 pol455
cHBV42 48 M 33 1123.66 48 Telbivudine env183, pol455 pol455
cHBV43 42 F <10 163.41 15 Tenofovir core18, pol455 core18, pol455
cHBV44 30 M <10 3049.44 28 Tenofovir env183, pol455 env183, pol455
cHBV45 33 F <10 3409.61 56 Tenofovir core18, env183, pol455 core18, pol455
cHBV46 41 M <10 927.04 19 Tenofovir env183, pol455 pol455
cHBV47 61 F <10 483.26 24 Tenofovir env183, pol455 – 
cHBV48 56 F <10 592.12 30 Tenofovir env183, pol455 env183
cHBV49 43 F <10 138.71 20 Tenofovir env183 env183
ALT, alanine transaminase; cHBV, chronic HBV; F, female; HBsAg, HBV surface antigen; M, male; nd, not done; VL, viral load; WT, wild type.
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The higher detection rate of core18-specific CD8+ T cells was 
also associated with a higher frequency (figure 1D). However, 
env183-specific CD8+ T cells were only detectable in 25% (8/32) 
of patients with cHBV (figure 1C), so that further comparative 
analyses were focused on core18-specific versus pol455-specific 
CD8+ T cells.
Next, we performed a phenotypical analysis of the enriched 
core18-specific and pol455-specific CD8+ T cells. Of note, 
all core18-specific CD8+ T cells showed a phenotype of anti-
gen-experienced cells (being either CD45RA+CCR7−; 
CD45RA-CCR7−; or CD45RA-CCR7+; figure 1E). In contrast, 
a subset of pol455-specific CD8+ T cells showed a naive-like 
phenotype characterised by the coexpression of CD45RA and 
CCR7. Importantly, the naive-like phenotype of these virus-spe-
cific CD8+ T cells is not associated with viral escape muta-
tions and consequent loss of antigen recognition since we only 
included T cell responses of patients with matched autologous 
viral sequences in this study. These results indicate that all 
core18-specific CD8+ T cells have been primed in vivo, while a 
subset of pol455-specific CD8+ T cells might either not have been 
primed or may exhibit a naive-like phenotype due to abortive 
activation. Thus, for comparability reasons, we only included 
patients in our further analyses that harboured pol455-specific 
CD8+ T cell responses with >80% antigen-experienced cells.
Increased expansion capacity of core18-specific versus pol455-
specific CD8+ T cells
Next, we analysed core18-specific and pol455-specific CD8+ T 
cells for their expansion capacity and cytokine production. For 
this, HBV-specific CD8+ T cells were expanded for 2 weeks 
after stimulation with the respective peptides. As shown in 
figure 2A,B, core18-specific CD8+ T cells displayed a signifi-
cantly higher interferon γ (IFNγ) production compared with 
pol455-specific CD8+ T cells after in vitro expansion. This was 
also reflected by a better expansion capacity of core18-specific 
CD8+ T cells (figure 2C). Of note, the expansion capacity 
of core18- and pol455-specific CD8+ T cells did not correlate 
with HBsAg levels (online supplementary SI figure 1A). To 
determine whether the higher IFNγ production was only due 
to the better expansion capacity or also to increased effector 
functions of single cells, we determined the multifunctionality, 
assessed by coexpression of IFNγ, tumour necrosis factor (TNF) 
and CD107a in relation to the frequency of core18-specific 
and pol455-specific CD8+ T cells. However, we did not find a 
statistically significant better multifunctionality of core18-spe-
cific CD8+ T cells (figure 2D), indicating that the higher IFNγ 
production after expansion is most likely reflecting the higher 
frequency and not increased effector functions. This was further 
Figure 1 pMHC I tetramer-based magnetic bead enrichment of HLA*A02-restricted HBV-specific CD8+ T cells in patients with low viral load. (A) 
Representative flow cytometry analyses showing core18-specific, pol455-specific and env183-specific CD8+ T cells obtained from patients with cHBV 
before and after pMHC I tetramer-based enrichment. Frequency of core18, pol455 and env183 epitope-specific CD8+ T cells within the total CD8+ T cell 
population is indicated. Proportion of analysed cHBV patients with (depicted in black) and without (depicted in grey) detectable virus-specific 
(B) and epitope-specific (C) CD8+ T cells after performing pMHC I tetramer-based enrichment. Numbers of analysed patients are indicated. (D) 
Frequencies of enriched HBV epitope-specific among bulk CD8+ T cells in patients with cHBV. (E) Frequencies of enriched HBV epitope-specific CD8+ T 
cells with an antigen-experienced (CD45RA+CCR7-, CD45RA-CCR7- or CD45RA-CCR7+) phenotype in patients with cHBV. Dotted line indicates 
the cut-off value of >80% antigen-experienced cells used for further analyses. Each dot represents one epitope-specific CD8+ T cell population 
enriched from one individual patient. Median with IQR is indicated. Statistical analyses was performed via Mann-Whitney test (D and E) (*p<0.05; 
****p<0.0001). cHBV, chronic hepatatis B virus; pMHC I, peptide-loaded MHC I.
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supported by similar antiviral efficacies assessed in coculture 
experiments of HBV-infected hepatoma cells (HepG2-hNTCP) 
with either HBV-specific CD8+ T cell clones or patient-derived 
in vitro expanded HBV-specific CD8+ T cells (online supple-
mentary SI figure 2). Of note, we were not able to assess corre-
sponding antiviral efficacies of HBV-specific CD8+ T cells ex 
vivo since frequencies were too low for the required effector cell 
numbers in coculture experiments.18
As a possible indicator of the strength of HBV-specific 
CD8+ T cell responses in vivo, we analysed the occurrence of 
viral sequence variations within the respective epitope. Sequence 
variations were more frequent in the core18 epitope compared 
with the pol455 epitope (figure 2E) potentially suggesting 
stronger immune pressure mediated by core18-specific CD8+ T 
cells. Additionally, to estimate the in vivo expansion of HBV-spe-
cific CD8+ T cells after activation, we measured the precursor 
frequency of HBV-specific CD8+ T cells in HD, compared with 
the frequencies detectable in patients with cHBV (figure 2F). Of 
note, we only observed an increased frequency of core18-specific 
but pol455-specific CD8+ T cells in patients with cHBV compared 
with HD. This finding indicates a stronger in vivo expansion 
of core18-specific versus pol455-specific CD8+ T cells in cHBV 
Figure 2 Increased expansion capacity of core18-specific versus pol455-specific CD8+ T cells. (A) Representative flow cytometry analyses showing 
IFNγ production and tetramer staining of core18-specific and pol455-specific CD8+ T cells obtained from patients with cHBV after peptide-specific 
in vitro expansion for 14 days. (B) IFNγ production was analysed after restimulation for 5 hours. Frequency of IFNγ+ cells within the CD8+ T cell 
population is depicted. (C) Calculated expansion factor of core18-specific and pol455-specific CD8+ T cells. (D) Analysis of multifunctionality was 
performed by assessing the frequency of IFNγ+TNF+CD107a+CD8+ T cells of expanded peptide-specific populations relative to the pMHC I 
tetramer+ population. (E) Viral sequences of the epitopes targeted by the enriched HBV-specific CD8+ T cell populations were analysed by nested PCR. 
Proportions of patients harbouring wild type (WT; in grey) and variant (VAR; in black) viral sequences are depicted for HBV core18 and pol455 epitopes, 
respectively. (F) Frequencies of enriched HBV epitope-specific among bulk CD8+ T cells in HD compared with patients with cHBV. Each dot represents 
one epitope-specific CD8+ T cell population from one individual patient. Bars indicate the median with IQR. Statistical analysis was performed via 
Mann-Whitney test (B–D, F) (**p<0.05; ***p<0.001; ****p<0.0001). cHBV, chronic HBV; HD, healthy donors; pMHC I, peptide-loaded MHC I; TNF, 
tumour necrosis factor.
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infection. In sum, these data demonstrate that core18-specific 
compared with pol455-specific CD8+ T cells are superior in their 
functional capacity in vitro and in vivo.
Higher KLRG1 and Eomes expression in pol455-specific versus 
core18-specific CD8+ T cells
Next, we asked whether the functional differences between 
core18-specific and pol455-specific CD8+ T cells are linked to 
a differential phenotypical expression of markers indicative of 
exhaustion in a chronic infection (PD1, 2B4, TIGIT, KLRG1 and 
CD39). We could detect a higher frequency of KLRG1+ cells in 
pol455-specific compared with core18-specific CD8+ T cell popu-
lations, while the proportion of HBV epitope-specific CD8+ T 
cells expressing PD1, TIGIT, 2B4 and CD39 was similar 
(figure 3A and online supplementary SI figure 3A). Interestingly, 
the expression level of PD1 was increased on core18-specific 
CD8+ T cells (online supplementary SI figure 3C). However, 
this was not evident for any other inhibitory receptor. Further-
more, we also analysed expression of the transcriptions factors 
Eomes and T-bet since high expression of Eomes accompanied 
by low levels of T-bet has been linked to T cell exhaustion. 
Here, we found no difference in T-bet but a significantly higher 
Figure 3 Decreased expression of KLRG1 and Eomes in core18-specific versus pol455-specific CD8+ T cells. Ex vivo expression analyses of inhibitory 
receptors PD1, TIGIT, 2B4 and KLRG1 (A) and transcription factors Eomes and T-bet (B) in enriched HBV epitope-specific CD8+ T cells obtained from 
patients with cHBV. (C) Expression of PD1, KLRG1, Eomes and T-bet of HLA-A*02-restricted core18 and pol455-specific CD8+ T cells compared with 
HLA-A*11-restricted core141 and HLA-B*35-restricted pol173-specific CD8+ T cell populations, respectively. Frequencies refer to cells positive for the 
respective marker within the indicated HBV-specific CD8+ T cell populations. Naive-like (CD45RA+CCR7+) HBV epitope-specific CD8+ T cells were 
excluded from marker expression analyses. Each dot represents one epitope-specific CD8+ T cell population enriched from one individual patient. Bars 
indicate the median with IQR. The following statistical analyses were performed: Mann-Whitney test (A and B: T-bet), unpaired t-test with Welch’s 
correction (A: KLRG1, B: Eomes) and two-way analysis of variance with Sidak’s multiple comparison test (C) (*p<0.05; **p<0.01).
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fraction of Eomes+ cells among pol455-specific versus core18-spe-
cific CD8+ T cells (figure 3B). The fractions of Eomes+ 
core18-specific and pol455-specific CD8+ T cells were increased 
in cHBV compared with patients with rHBV (online supplemen-
tary SI table 2, SI figure 3D). Of note, T-bet levels were interme-
diate in HBV-specific CD8+ T cells targeting core18 and pol455 
epitopes (figure 3B; online supplementary SI figure 3B). Thus, a 
higher fraction of pol455-specific compared with core18-specific 
CD8+ T cells obtained from patients with cHBV exhibited a 
typical profile of severe Eomes+T-betint T cell exhaustion that 
is also in agreement with the lower expansion capacity of these 
cells (online supplementary SI figure 3E). The profile indica-
tive of T cell exhaustion did not correlate with serum HBsAg 
levels of analysed patients with cHBV (online supplementary SI 
figure 1B). Importantly, the phenotypic characteristics of HBV 
epitope-specific CD8+ T cells were similar when extending our 
analyses on CD8+ T cell populations targeting the HLA-A*11-re-
stricted core141 and the HLA-B*35-restricted pol173 epitope 
(online supplementary SI table 1, SI figure 4 and figure 3). Thus, 
these data clearly suggest that phenotypic profiles of HBV-spe-
cific CD8+ T cells in cHBV infection differ with respect to the 
targeted antigen.
Core18/141-specific and pol455/173-specific CD8+ T cells differ in 
their T cell subset distribution in chronic infection
Based on CD127/PD1 coexpression, we could recently define 
two distinct epitope-specific CD8+ T cell subsets in chronic 
HCV (cHCV) infection that significantly differ in their func-
tional and phenotypical characteristics: a CD127+PD1+ memo-
ry-like population and a more severely exhausted CD127-PD1+ 
subset (figure 4A). Thus, we asked whether core18/141-specific 
and pol455/173-specific CD8+ T cells differ in their T cell subset 
distribution. Interestingly, in comparison with HCV (figure 4A), 
HBV-specific CD8+ T cells display a different T cell subset distri-
bution during chronic infection with a higher proportion of cells 
Figure 4 Core18/141-specific and pol455/173-specific CD8+ T cells differ in their CD127/PD1-based subset distribution in low viral load patients. CD127/
PD1 coexpression analysis of enriched HCV NS31073-specific (A) and HBV epitope-specific (B) CD8+ T cells obtained from cHCV and cHBV patients, 
respectively. Frequencies refer to CD127+PD1+ and CD127-PD1+ cells within the epitope-specific CD8+ T cell population. CD38 expression of enriched 
core18/141-specific versus pol455/173-specific CD8+ T cells from patients with cHBV ex vivo (C) and in comparison with CD38 expression after peptide-
specific in vitro expansion (D). (E) Expression of CD38 (left) and proportion of memory-like CD127+PD1+ cells (right) within the HBV epitope-specific 
CD8+ T cell population in treatment-naive (median viral load: 2.96×106 IU/mL) compared with nucleos(t)ide analogue (NUC)-treated patients (median 
viral load: 12 IU/mL). Naive-like (CD45RA+CCR7+) epitope-specific CD8+ T cells were excluded from marker expression analyses. Each dot represents 
one epitope-specific CD8+ T cell population from one individual patient. Bars indicate the median with IQR. Statistical analysis was performed via 
Mann-Whitney test (B–D) (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001). cHBV, chronic HBV; cHCV, chronic HCV.
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within the memory-like subset (figure 4B). However, within the 
HBV-specific population, we found significant differences between 
core18/141-specific and pol455/173-specific CD8+ T cells. Indeed, as 
shown in figure 4B, core18/141-specific CD8+ T cells were more 
frequently found in the memory-like T cell subset compared with 
pol455/173-specific CD8+ T cells. Based on previous findings from 
our group in cHCV infection showing that antigen stimulation is the 
main driver of terminal T cell exhaustion and thus contributing to 
T cell subset distribution, we hypothesised that differential antigen 
stimulation may also explain the differences between core18/141-spe-
cific and pol455/173-specific CD8+ T cells. To address this issue, we 
analysed the epitope-specific populations for their expression of 
CD38 as a marker for T cell activation and recent T cell receptor 
(TCR) triggering. As shown in figure 4C, we found a higher expres-
sion of CD38 on pol455/173-specific versus core18/141-specific CD8+ 
T cells indicating that pol455/173-specific CD8+ T cells are most 
likely more activated in vivo and that this may lead to a reduced 
frequency of memory-like CD127+PD1+CD8+ T cells compared 
with core18/141-specific CD8+ T cells. The overall low expression 
of CD38 on core18/141-specific and pol455/173-specific CD8+ T cells 
during cHBV infection cannot be explained by intrinsic T cell 
defects since HBV epitope-specific TCR stimulation in vitro led 
to rapid CD38 upregulation (figure 4D). Thus, the low CD38 
expression, also in comparison with HCV-specific CD8+ T cells 
(online supplementary SI table 3, SI figure 5A) is probably due to 
the low viral load present in our cohort of patients with cHBV. This 
assumption is further supported by the finding that pol455/173-spe-
cific and core18/141-specific CD8+ T cells from patients with cHBV 
undergoing nucleos(t)ide analogue (NUC) treatment exhibited 
reduced CD38 expression after NUC-mediated viral control (online 
supplementary SI table 4 and figure 4). Importantly, reduced CD38 
expression after NUC treatment was associated with a higher frac-
tion of memory-like pol455/173-specific CD8+ T cells. Based on the 
fact that core18/141specific CD8+ T cells have an exclusively memo-
ry-like phenotype before NUC treatment, no further increase could 
be observed (figure 4E). In this context, it is also noteworthy that we 
did not observe differences in CD38 expression and memory-like 
CD127+PD1+ subset distribution within our cohort of patients 
with low viral load when we compared inactive HBsAg carriers and 
NUC-treated patients (online supplementary SI figure 5B). Hence, 
antigen recognition in cHBV patients with low viral load is linked to 
the predominance of memory-like HBV-specific CD8+ T cells but 
probably differs with respect to the targeted antigen.
Dysregulated BCL2 expression in pol455/173-specific CD8+ T 
cells results in defective expansion capacity in cHBV infection
Next, we asked whether the different subset distribution of 
core18/141-specific versus pol455/173-specific CD8+ T cells may 
explain the differential expansion capacity of these cells. As 
shown in figure 5A, we indeed found a clear correlation between 
the expansion factor and frequency of memory-like core18/141-spe-
cific CD8+ T cells. Surprisingly, however, such a correlation 
was not observed for pol455/173-specific CD8+ T cells (figure 5A). 
Since the transcription factor TCF1 has been shown to best deter-
mine the memory-like phenotype and since it has been linked 
to the proliferative capacity of this T cell subset,19 20 we next 
stained both HBV epitope-specific T cell populations for TCF1 
expression. We did not find a differential expression of TCF1 
within the overall and the memory-like core18/141-specific and 
pol455/173-specific CD8+ T cell populations (figure 5B) suggesting 
that the differential expansion capacity cannot be attributed to 
distinct TCF1-associated proliferative capacities of the respec-
tive T cell populations. Next, we asked whether core18/141-specific 
and pol455/173-specific CD8+ T cells differ in their survival poten-
tial. To address this question, we stained HBV epitope-specific 
CD8+ T cells for the expression of the antiapoptotic molecule 
BCL2. Importantly, we found a significantly lower expression 
of BCL2 in pol455/173-specific compared with core18/141-specific 
CD8+ T cells. The different expression was evident in both the 
overall antigen-specific CD8+ T cell population and the memo-
ry-like subset (figure 5C). We also found a correlation between 
the expansion factor and the presence of cells highly positive for 
BCL2 (figure 5D).
To dissect whether the dysregulated TCF1/BCL2 expression in 
pol455/173-specific CD8+ T cells is a hallmark of viral persistence, 
we further analysed HBV-specific CD8+ T cells obtained from 
rHBV patients (online supplementary SI table 2). Importantly, 
we did neither find a dysregulated TCF1/BCL2 expression nor 
different expansion capacities of pol455-specific versus core18-spe-
cific CD8+ T cells after rHBV infection (figure 5E).
These results suggest that the different expansion of 
core18/141-specific versus pol455/173-specific CD8+ T cells in 
chronic infection is not primarily due to a differential prolifera-
tive capacity but rather to different survival characteristics.
DISCUSSION
By using pMHC I tetramer-based enrichment and thereby 
increasing the detection sensitivity of HBV-specific CD8+ T cells 
in the peripheral blood of patients with cHBV, our study gives 
novel insights into the immunodominance, function and pheno-
typical properties of the HBV-specific CD8+ T cell response.
The first important finding of our study is that HBV-specific 
CD8+ T cells are present in the majority of cHBV patients with 
low viral load. Indeed, we were able to detect HBV-specific 
CD8+ T cells ex vivo in about 80% of patients clearly suggesting 
that the previously reported low detection rate of core18-specific 
and pol455-specific CD8+ T cells
1–6 8 cannot be explained by a 
complete deletion of virus-specific CD8+ T cells. Our finding 
is in agreement with a recent study from the group of Bertoletti 
also reporting the common existence of HBV-specific CD8+ T 
cells in a patient cohort with low or undetectable viral load 
due to antiviral therapy with NUCs.21 Importantly, env183-spe-
cific CD8+ T cells were only detectable in a minor fraction of 
tested cHBV patients with low viral loads suggesting that limited 
presence of env183-specific CD8+ T cells may impair efficient 
responses in cHBV infection.
The higher detection rate of antigen-specific CD8+ T cells by 
pMHC I tetramer-based enrichment revealed previously unappre-
ciated differences between core18-specific and pol455-specific CD8+ 
T cells. In particular, core18-specific compared with pol455-specific 
CD8+ T cells were present in a higher frequency and displayed a 
predominant antigen-experienced phenotype in all tested patients 
indicating a higher immunogenicity of the HBV core protein. In 
contrast, some pol455-specific CD8+ T cells displayed a naive-
like phenotype despite the presence of cognate antigen. Thus, as 
has also been shown in HCV infection,22 these results reveal the 
presence of phenotypically diverse HBV-specific CD8+ T cells in 
cHBV infection. They also suggest that some pol455-specific CD8+ 
T cells are inefficiently recruited to the effector T cell pool and 
present a naive-like phenotype due to abortive activation. This is 
further supported by the reduced in vivo expansion of pol455-spe-
cific CD8+ T cells that result in low frequencies hardly differing 
from naive precursor frequencies. The mechanisms responsible 
for the different frequencies and phenotypes of core18-specific and 
pol455-specific CD8+ T cells remain unclear. The overall cytokine 
milieu in patients with cHBV was most likely not responsible for 
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Figure 5 Dysregulated TCF1/BCL2 expression determines impaired expansion capacity of pol455/173-specific CD8+ T cells in cHBV patients with 
low viral load. (A) Correlation analyses of the expansion and the frequency of memory-like CD127+PD1+ core18/141-specific and pol455/173-specific 
CD8+ T cells. Expression of TCF1 (B) and BCL2 (C) were assessed on enriched core18/141-specific and pol455/173-specific CD8+ T cells (left panel) and the 
respective memory-like CD127+PD1+ subsets (right panel). (D) Correlation analyses of the expansion and the frequency of BCL2high-expressing HBV-
specific CD8+ T cells. HBV-specific CD8+ T cells obtained from rHBV patients were analysed for the expression of TCF1 (left) and BCL2 (middle) and 
their expansion capacity (right). Naive-like (CD45RA+CCR7+) HBV epitope-specific CD8+ T cells were excluded from marker expression analyses. Each 
dot represents one epitope-specific CD8+ T cell population from one individual patient. Bars indicate the median with IQR. The following statistical 
analyses were performed: linear regression analyses (A, D), Mann-Whitney test (B: left panel, D) and unpaired t-test with Welch’s correction (B: right 
panel, C) (*p<0.05; ***p<0.001). cHBV, chronic HBV; rHBV, resolved HBV.
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the occurrence of naive-like HBV-specific CD8+ T cells since we 
were able to detect HBV epitope-specific CD8+ T cell populations 
with distinct phenotypes, more specifically antigen-experienced 
core18-specific and naive-like pol455-specific CD8+ T cells, in the 
same cHBV donor. Noteworthy, HBV core and pol proteins are 
produced in different quantities in HBV-infected cells with signifi-
cantly higher levels of core.23 Since the level of antigen presented on 
hepatocytes may dictate T cell frequencies23 as well as T cell func-
tion,24 it is tempting to speculate that this contributes to the higher 
priming capacity and subsequent higher frequency of core18-spe-
cific versus pol455-specific CD8+ T cells. In addition, differences 
in antigen processing and presentation as well as in HLA binding 
and TCR affinity may also influence the frequencies, phenotype 
and function of HBV-specific CD8+ T cells. Further studies are 
definitely required to clarify this point, for example, by analysing 
T cell responses towards HBV-infected target cells. In this context, 
it is interesting to note that in comparison with the pol455 peptide, 
the core18 peptide has been reported to have a higher HLA binding 
affinity and an increased cross-reactive behaviour.25 In line with this 
observation, core18-specific CD8+ T cell responses can be detected 
in the context of different HLA-A*02 alleles25 26 supporting a highly 
cross-reactive priming capacity of core18. Clearly, future studies 
have to address how the finding of different frequencies and pheno-
types of circulating core18-specific versus pol455-specific CD8+ T 
cells translates into the intrahepatic compartment. In this regard, it 
will be important to dissect antigen-specific and tissue-specific influ-
ences27 on intrahepatic HBV-specific CD8+ T cells.
We also observed functional differences between the two HBV 
epitope-specific CD8+ T cell populations with core18-specific 
CD8+ T cells showing a significantly better expansion capacity. 
This was not reflected by the fraction of PD1+ cells since PD1 was 
detectable on nearly all HBV-specific CD8+ T cells irrespective of 
their antigen specificity. Thus, this finding supports the assump-
tion that PD1 is not a definitive marker for complete functional 
exhaustion but can also be expressed on at least partially functional 
T cells in the context of a chronic infection.16 19–21 28 29 Further-
more, in the lymphocytic choriomeningitis virus mouse model, PD1 
has even been shown to prevent virus-specific CD8+ T cells from 
terminal exhaustion and to contribute to the survival of memory T 
cell populations.30 In line with this, elevated PD1 expression levels 
on core18-specific CD8+ T cells may be linked to their otherwise 
less severely exhausted characteristics compared with pol455-specific 
CD8+ T cells.
In addition to PD1, we also detected expression of inhibitory 
receptors such as 2B4, KLRG1 and TIGIT on a large fraction of 
both HBV epitope-specific CD8+ T cell populations. These results 
are in agreement with several previous studies reporting that 
HBV-specific CD8+ T cells in cHBV infection are characterised 
by expression of PD1 and other inhibitory receptors indicative of 
CD8+ T cell exhaustion.5 8 10–14 Interestingly, in comparison with 
core18-specific CD8+ T cells, significantly more pol455-specific 
CD8+ T cells expressed KLRG1 suggesting further antigen-me-
diated differentiation.31 32 In addition, we also found differences 
between core18-specific and pol455-specific CD8+ T cells on the 
transcription factor level. In fact, we observed a higher Eomes 
expression in pol455-specific CD8+ T cells accompanied by an 
equally low T-bet expression. Hence, in cHBV infection pol455-spe-
cific compared with core18-specific CD8+ T cells exhibit dysreg-
ulated Eomes/T-bet expression ratios that more closely resemble 
the pattern that has been associated with terminal exhaustion.29 Of 
note, in rHBV infection, Eomes expression of HBV-specific CD8+ 
T cells was reduced compared with cHBV patients with an even 
lower fraction of Eomes+ pol455-specific CD8+ T cells. The frac-
tion of Eomes-expressing HBV-specific CD8+ T cells correlated 
with their expansion capacity, further supporting the association 
of dysregulated Eomes expression and T cell dysfunction in cHBV 
infection. Importantly, the phenotypic and functional differences 
of HBV core-specific and pol-specific CD8+ T cells were similar 
comparing HLA-A*02 and non-HLA-A*02-restricted epitopes in 
cHBV infection and are therefore most probably determined by the 
targeted antigen.
Exhausted virus-specific CD8+ T cell populations in chronic 
infections are not homogeneous but rather consist of heterogeneous 
subsets of less differentiated progenitor/memory-like and further 
differentiated/terminally exhausted cells.16 19 20 28 29 33 Interestingly, 
memory-like cells predominated in all tested HBV epitope-specific 
CD8+ T cell populations of our cohort with low viral loads probably 
reflecting low ongoing antigen stimulation. However, in line with 
the advanced differentiation towards terminal exhaustion reflected 
by a higher proportion of KLRG1 and Eomes expressing cells, 
we also found a decreased frequency of CD127+PD1+ memo-
ry-like cells among CD8+ T cells targeting pol455/173 compared with 
core18/141. In HCV infection, we have previously reported that this 
memory-like subset is maintained after antigen removal on treat-
ment with direct-acting antivirals but that ongoing antigen trig-
gering diminishes the frequency of this subset.16 Thus, the decreased 
frequency of memory-like pol455/173-specific CD8+ T cells indicates 
stronger ongoing antigen stimulation of these cells compared with 
core18/141-specific CD8+ T cells. The higher antigen triggering of 
pol455/173-specific CD8+ T cells is further supported by the higher 
CD38 expression observed in our study. In sum, based on the 
distinct expression of KLRG1, Eomes and CD38 and reflected by 
the differential CD127/PD1-based T cell subset distribution, our 
results indicate that pol455/173-specific CD8+ T cells probably receive 
more sustained stimulation and are thus more severely exhausted in 
vivo compared with core18/141-specific CD8+ T cells. In this context, 
it is also important to note that we observed, in line with previous 
studies,34 a higher mutation rate within the core18 epitope versus 
the pol455 epitope further indicating a higher pol455-specific T cell 
exhaustion and thus reduced viral evolution pressure by pol455-spe-
cific CD8+ T cells also in patients with cHBV.
The frequency of the memory-like CD127+PD1+ subset clearly 
correlated with the expansion capacity of core18/141-specific 
CD8+ T cells. However, no correlation was evident with regard 
to pol455/173-specific CD8+ T cells. This was a surprising finding 
since expansion capacity has been previously associated with the 
frequency of memory-like virus-specific CD8+ T cells in HCV 
infection.16 In HCV infection, the memory-like HCV-specific 
CD8+ T cell subset is determined by the expression of TCF1 that 
has been linked to the proliferative capacity of these cells.16 Interest-
ingly, core18/141-specific and pol455/173-specific CD8+ T cells and the 
respective memory-like CD127+PD1+ subsets expressed TCF1 
at equal frequencies. Thus, TCF1 does probably not exclusively 
determine the differential expansion capacities of HBV epitope-spe-
cific CD8+ T cell populations. Next to proliferation, virus-spe-
cific CD8+ T cell expansion requires T cell survival. Of note, we 
observed lower expression of the antiapoptotic molecule BCL2 
in pol455/173-specific versus core18/141-specific CD8+ T cells and 
the expression of BCL2 correlated with the expansion of the two 
HBV-specific CD8+ T cells. These results therefore clearly suggest 
that the differential BCL2 expression is linked to the different 
expansion capacities of core18/141-specific versus pol455/173-specific 
CD8+ T cells and pinpoint to distinct molecular mechanisms of 
HBV-specific CD8+ T cell failure targeting cognate core and pol 
antigens. Furthermore, these data also reveal that a balanced expres-
sion of TCF1 and BCL2 is essential for the superior expansion char-
acteristics of memory-like subsets among exhausted virus-specific 
CD8+ T cells in general. Thus, the combined capacity to proliferate 
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and to survive determines memory-like characteristics of T cells in 
chronic infection.
In sum, the results of our study reveal on the one hand that, in 
cHBV infection, the molecular mechanisms underlying impaired 
circulating T cell responses differ with respect to the targeted HBV 
antigens core versus pol. However, regarding chronic infection in 
general, we specified key characteristics of targetable virus-specific 
CD8+ T cell subsets in greater depth, namely proliferation accom-
panied by survival. Both aspects have relevance for the design of 
future immunotherapeutic approaches in HBV cure that aim to 
expand CD8+ T cell responses within the peripheral blood, the best 
accessible site for intervention.
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